Skip to content

Galaxy Diagnostics

7 viewers · 30d

Total raised

$7.2M

+$3.0M this year

2 filings since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $3.0M
ROUNDS
2
INVESTORS
55
FOUNDED
N/A
HQ
Research Triangle Park, NC
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
7

AI overview

Updated

Galaxy Diagnostics, Inc. specializes in advanced testing solutions designed to detect elusive flea- and tick-borne pathogens, specifically *Bartonella* species, which are often missed by standard diagnostic methods. By enhancing clinical detection, the company aims to improve patient outcomes and strengthen the connection between human and animal health.

What sets it apart

Galaxy Diagnostics stands out for its proprietary Bartonella Digital ePCR™ Platform, which significantly increases diagnostic sensitivity for difficult-to-detect infections.

Funding history

2 rounds
EquityMay 1, 2026
Form D
+$3.0M$7.2M total
EquityApr 9, 2025
Form D
+$4.1M$4.1M total

Products

1 tracked

Bartonella Digital ePCR™ Platform

Diagnostics

This platform utilizes droplet digital PCR (ddPCR) alongside the patented Bartonella alphaproteobacteria growth medium (BAPGM™) to effectively enrich samples and directly detect *Bartonella* DNA, leading to enhanced diagnostic sensitivity compared to traditional methods.

  • High sensitivity with direct detection of *Bartonella* DNA
  • Combination of ddPCR and BAPGM™ for effective sample enrichment
  • Applicable for both human and animal samples

Links

WebsiteSEC EDGAR filings